Abstract C200: Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro.
Jason M. Foulks(Astex Pharmaceuticals), Steven B. Kanner(Energy Biosciences Institute), Kan Ho(Astex Pharmaceuticals), Ashley Chan(Astex Pharmaceuticals), Benjamin Brenning(Astex Pharmaceuticals), Shannon Merx(Astex Pharmaceuticals), Anna V. Senina(Astex Pharmaceuticals), Marcus Wilkes(Astex Pharmaceuticals), Yong Xu(Jinan University), David Vollmer(Astex Pharmaceuticals), Xiaohui Liu(Hebei Medical University), Jihua Liu(China Pharmaceutical University), Li‐Wen Huang(University of California, San Francisco), Shuping Lai(Astex Pharmaceuticals), Michael Saunders(Astex Pharmaceuticals), Michael V. McCullar(Astex Pharmaceuticals), Adrianne Clifford(Astex Pharmaceuticals), Bai Luo(Central South University)
Cited by 1
Related Papers
Psychological stress and the subsequent appearance of new brain MRI lesions in MS
|Neurology|2000|192
Paracrine Action of Mesenchymal Stem Cells Revealed by Single Cell Gene Profiling in Infarcted Murine Hearts
|PLoS ONE|2015|93